Tomatoes Recalled in 14 States as FDA Sets Highest Risk Level
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Two separate recalls have been classified as Class I, the most serious warning level, by the Food and Drug Administration (FDA) because of potential salmonella contamination in raw tomato products distributed across multiple U.S. states.
The ongoing recalls, both initiated voluntarily by the distributing firms, involve tomatoes produced by Williams Farms Repack LLC under the brand name Hanshaw & Capling Farm (or H&C Farms) in Immokalee, Florida, and by Ray & Mascari Inc. of Indianapolis.
Newsweek has contacted Ray & Mascari Inc. for comment via email outside regular working hours and Williams Farms Repack LLC via phone.
Why It Matters
The recalls affect large quantities of tomatoes distributed across a number of states and include both retail and bulk packaging. The potential contamination with salmonella—a bacteria that can cause serious and sometimes fatal infections in young children, elderly people and those with weakened immune systems—determines the high level of risk to consumers associated with the recall.
Healthy persons infected with salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. In rare circumstances, infection with salmonella can result in the organism getting into the bloodstream and producing more severe illnesses, such as arterial infections (i.e., infected aneurysms), endocarditis and arthritis.
A stock image of ripe tomatoes.
A stock image of ripe tomatoes.
Winfried Rothermel/dpa via AP
What To Know
The recall from Williams Farms Repack involves 3,651 boxes of "H&C Farms Raw Premium Tomatoes, Naturally Grown from Seed" packaged in various sizes ranging from jumbo to 6x7, with all requiring refrigeration.
The affected lot is marked as 098 14TO3-1. The product was distributed in Texas, Illinois, Wisconsin, South Carolina, Florida, Tennessee, Indiana and Massachusetts.
The recall was initiated on April 29 and classified by the FDA on May 13.
Separately, Ray & Mascari issued a recall of 510 cases of vine ripe tomatoes. The products were contained in clamshell packages and several bulk packaging sizes. Affected lot numbers range from RM 250420 to RM 250427.
The tomatoes were distributed across Indiana, Kentucky, Massachusetts, Maryland, Michigan, North Carolina, Ohio, Pennsylvania and Wisconsin.
The recall was initiated on April 30 and classified by the FDA on May 13.
While no illnesses have been publicly linked to these products, the Class I designation indicates that use of or exposure to them may cause serious adverse health consequences or death.
What People Are Saying
The FDA said on its website: "Most people infected with Salmonella will begin to develop symptoms 12 to 72 hours after infection. The illness, salmonellosis, usually lasts four to seven days and most people recover without treatment. Most people with salmonellosis develop diarrhea, fever, and abdominal cramps.
"More severe cases of salmonellosis may include a high fever, aches, headaches, lethargy, a rash, blood in the urine or stool, and in some cases may become fatal. The U.S. Centers for Disease Control and Prevention estimated that approximately 450 persons in the United States die each year from acute salmonellosis.
"Due to the range in severity of illness, people should consult their healthcare provider if they suspect that they have developed symptoms that resemble a Salmonella infection."
What Happens Next
Both recalls remain ongoing. Consumers are advised to check for the listed lot numbers and discard any affected products.
Consumers who have purchased the Ray & Mascari products and have questions or reports of any illness may contact the company at 1-317-637-0234 between Monday and Saturday from 6 a.m. to 5 p.m. ET. Consumers who purchased the Williams Farm Repack products may contact the company at 843-866-7707 or 843-599-5154 between Monday and Friday from 8 a.m. to 5 p.m. ET.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Many people using OTC birth control pills previously used nothing, study finds
Two years after the U.S. Food and Drug Administration approved the first over-the-counter birth control pill, new research is looking at who's switching to it and why. In the study, published Monday in JAMA Network Open, researchers used survey data from 986 people, ages 15 to 45, in 44 states who obtained the over-the-counter pill either online or at a pharmacy. They found that a significant portion of users shifted to the over-the-counter pill from a less-effective method of birth control or from using no contraception at all. Of those surveyed, they found a 31.8 percentage point increase in use by people who previously used no contraceptive method. A 41 percentage point increase was seen in those who switched from a less-effective method, like condoms or emergency contraception. Opill, the over-the-counter, progestin-only pill from drugmaker Perrigo, provides an option for obtaining oral contraceptives without needing to first see a health care provider. Allowing people to access the pill without a prescription was done in hopes of reducing barriers to access, according to the FDA's news release at the time of approval, which noted that almost half of the 6.1 million pregnancies in the U.S. each year are unintended. The new research "is one of the first studies to show that over-the-counter birth control pills are reaching the very people they're meant to help — those who face the greatest barriers to care," lead author Dr. Maria Rodriguez, professor of obstetrics and gynecology in the Oregon Health & Science University School of Medicine, said in a news release. Those accessing the over-the-counter pill were more likely than prescription users to be uninsured, younger (ages 15-20) and living in rural areas, according to the study. The most common reason people gave in the survey for choosing the OTC pill was that it didn't require an appointment, followed by those who said they didn't have a regular physician. "At a time when pregnancy is becoming even more dangerous in the United States — especially for people of color, those with low incomes, and those living in rural communities — our findings underscore that OTC contraception is a powerful tool for reproductive autonomy," Rodriguez said. Alaska Sen. Dan Sullivan on the Trump-Putin summit, sanctions and more Laufey on creating her own sound A robotics activist's remarkable crusade Solve the daily Crossword
New York Times
an hour ago
- New York Times
A Common Weight Loss Drug Can Treat Severe Liver Disease, F.D.A. Says
The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on Friday. Roughly 15 million people — six percent of adults in the United States — have metabolic dysfunction-associated steatohepatitis, known as MASH. Rates of the disease are rising. The condition occurs when fat builds up in the liver, which can trigger scarring, cell damage and inflammation. MASH can lead to liver cancer and even death; it is also one of the most common reasons Americans seek liver transplants. Wegovy, which is a weekly injection, is now approved for adults with MASH and moderate-to-advanced levels of fibrosis, or excessive scar tissue in the liver. The drug is not intended for people with cirrhosis, a condition marked by severe liver scarring and damage. Novo Nordisk, the company that makes Wegovy and its sister drug, Ozempic, asked regulators to green-light the new approval after submitting data from a highly anticipated clinical trial. In the study, around 63 percent of people who took the drug saw fat and inflammation clear up in their livers, without worsening liver scarring, compared to about 34 percent of participants on a placebo. 'It's definitely exciting, and helping move beyond the stigma that we're just cosmetically treating weight,' said Dr. Andrew Kraftson, a clinical associate professor in the division of metabolism, endocrinology and diabetes at Michigan Medicine. 'There are these metabolic benefits that we're seeing with these medicines.' Scientists don't entirely understand how the drug helps treat MASH. It may, in part, be as simple as weight loss: MASH is closely linked with obesity, and Wegovy lowers body weight. But researchers think the drug may have other beneficial effects, like potentially reducing inflammation in the liver. Want all of The Times? Subscribe.
Associated Press
2 hours ago
- Associated Press
The Assistance Fund Opens New Program for Bronchiectasis
Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Bronchiectasis ORLANDO, FL / ACCESS Newswire / August 18, 2025 / The Assistance Fund, an independent charitable patient assistance organization that helps patients and families facing high medical out-of-pocket costs, today announced the launch of a new copay assistance program for people living with bronchiectasis. The program is designed to help eligible individuals pay for their out-of-pocket medical costs for treatment, such as copays, coinsurance, and deductibles. Bronchiectasis is a chronic lung disease where people are unable to properly clear mucus. People living with bronchiectasis experience a buildup of mucus in the lungs that can cause infections and coughing fits. Nearly half a million Americans currently live with bronchiectasis. [1] 'Living with bronchiectasis means more than managing a chronic lung condition-it involves unpredictable flare-ups, ongoing treatment, and the financial strain of affording those costs,' said Danielle Vizcaino, President and CEO of The Assistance Fund. 'Thanks to our generous donors, our Bronchiectasis Copay Assistance Program helps ease that burden, allowing people to focus on their health rather than the next medical bill.' To learn more or determine eligibility for financial support, visit or call (833) 426-2085 to speak with a Patient Advocate. A list of all the disease programs available from The Assistance Fund can be found on the website About The Assistance Fund The Assistance Fund (TAF) is an independent charitable patient assistance organization that helps patients and families facing high medical out-of-pocket costs by providing financial assistance for their copayments, coinsurance, deductibles, and other health-related expenses. The Assistance Fund currently manages nearly 100 disease programs, each of which covers all the FDA-approved medications that treat a specific disease named in the disease program. Since its founding in 2009, TAF has helped over 210,000 children and adults access the treatment they need to stay healthy or manage a life-changing disease. To learn more about The Assistance Fund, or for information on how to donate, please visit Media Contact Margaret Figley Senior Director of Communications [email protected] [1] Cleveland Clinic, 'Bronchiectasis,' accessed August 2025. SOURCE: The Assistance Fund (TAF) press release
